Trump Signs EO Fast-Tracking Psychedelic Research for Veterans (Psilocybin, Ibogaine, MDMA)

Trump signed an executive order April 17, 2026 directing the FDA to fast-track reviews for psychedelic drugs including psilocybin, ibogaine, LSD, and MDMA — targeting veterans with PTSD and depression. HHS Secretary RFK Jr. and Joe Rogan attended the Oval Office signing. The FDA simultaneously cleared the first ibogaine IND application. DEA and DOJ were directed to initiate Schedule I rescheduling reviews for substances completing Phase 3 trials.